GYLDEN PHARMA

Precision Intradermal Therapeutics

Leveraging the unique biology of the dermis for rapid systemic delivery and precision immune activation.

One biological foundation.

Two proprietary platforms.

PLATFORM l

Titanium Microneedle Platform

Rapid systemic delivery without injection.

Lead asset: Zograine™ for acute migraine.

PLATFORM ll

Gold Nanoparticle Platform

Programmable immune activation through dermal antigen-presenting cells.

Applications: vaccines and oncology.

Why the Dermis?

  • Dense capillary network.

  • Rich antigen-presenting cell environment.

  • Accessible route for self-administered therapy.

LEAD ASSET:

Zograine™

Better Delivery. Better Migraine Care.

  • Acute migraine treatment

  • Zolmitriptan titanium microneedle patch

  • 3-second application

  • Bypasses the GI tract

  • Planned NDA Submission

Development Pipeline

Biotech development progress across therapeutic programs and vaccine platforms.

Preclinical
Phase 1 / 2
Phase 3
Approval
Commercial
Zograine™
Phase 3 Complete
NDA Resubmission
COVID Vaccine
Clinical
Dengue Vaccine
Clinical
Chikungunya Vaccine
Preclinical, Phase 1 Approved
Oncology GNP
Exploratory
Ebola Vaccine
Exploratory

Built for Translation.

Clinical asset. Human vaccine data. GMP manufacturing.

Commercial microneedle facility.